Patent profile for the approved and in clinical trials Mpox vaccines.

Mpox disease was reported in 110 countries since May 2022, with 88,026 cases and 148 deaths by 21 June 2023. Although some drugs were already approved for Mpox treatment, the available smallpox vaccines can provide 85% cross-prevention, but there are no scientific publications describing the patent portfolio for Mpox vaccines. This paper aims to contribute to the identification of the status of the smallpox vaccine patents now applied for Mpox. We retrieved ten vaccines, but only a few had a patent portfolio and one under patent litigation processes in three continents. Also, no specific Mpox vaccine was retrieved and, in this sense, technological monitoring studies should be performed to provide a future vision regarding Mpox prophylaxis.

Citation

Irene von der Weid, Cristina d'Urso de Souza Mendes, Paula C Fonseca, Sandro G Viveiros Rosa. Patent profile for the approved and in clinical trials Mpox vaccines. Pharmaceutical patent analyst. 2023 May;12(3):103-111

Mesh Tags

Substances

PMID: 37671905

search → result